Real-world study evaluating the incidence of liver damage conditions in patients with primary liver cancer using immune checkpoint inhibitor-based combination therapy

• Published in: Zhonghua gan zang bing za zhi Vol. 30; no. 1; p. 57
• Main Authors: Hu, Y Q, Wang, N, Ran, X P, Cai, D C
• Format: Journal Article
• Language: Chinese
• Published: China 20-01-2022
• Subjects: Female; Humans; Immune Checkpoint Inhibitors; Incidence; Liver Neoplasms - epidemiology; Male; Retrospective Studies; Immune therapy; Liver damage; Immune checkpoint inhibitors; Immune-related adverse events; PD-1/PD-L1 antibody; Primary cancer
• ISSN: 1007-3418
• DOI: 10.3760/cma.j.cn501113-20210910-00466

To evaluate the incidence of immune checkpoint inhibitor-based combination therapy-induced liver damage in patients with primary liver cancer.
Clinical data of 65 hospitalized cases of primary liver cancer treated with programmed cell death-1 its ligand programmed death-ligand 1 (PD-1/PD-L1) antibody in the Department of Infectious Diseases of the Second Affiliated Hospital of Chongqing Medical University from January 1, 2018 to March 31, 2021 were retrospectively analyzed. The degree of liver injury before and after treatment was assessed according to CTCAE v5.0. Patients were grouped according to gender, age, presence or absence of cirrhosis, baseline Child-Pugh score, BCLC stage, and treatment regimen to compare the incidence of liver injury under different conditions. The χ (2) test or rank-sum test was used for comparison among multiple groups.
46 cases (70.77%) had liver damage of any grade according to the CTCAE V5.0 criteria during the treatment and observation period. All 6 cases who received standar